Literature DB >> 7628176

Success rates for new drugs entering clinical testing in the United States.

J A DiMasi1.   

Abstract

Mesh:

Substances:

Year:  1995        PMID: 7628176     DOI: 10.1016/0009-9236(95)90066-7

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  19 in total

1.  The distribution of sales revenues from pharmaceutical innovation.

Authors:  H G Grabowski; J Vernon
Journal:  Pharmacoeconomics       Date:  2000       Impact factor: 4.981

Review 2.  Narrowing the gap: access to HIV treatments in developing countries. A pharmaceutical company's perspective.

Authors:  J Cochrane
Journal:  J Med Ethics       Date:  2000-02       Impact factor: 2.903

3.  New drugs for osteoporosis. Comparison of the costs and required returns with those of other drugs intended for long-term use.

Authors:  M Edwards
Journal:  Pharmacoeconomics       Date:  1999-03       Impact factor: 4.981

4.  Emerging role of pharmacoeconomics in the research and development decision-making process.

Authors:  J A DiMasi; E Caglarcan; M Wood-Armany
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 5.  The effect of pharmacoeconomics on company research and development decisions.

Authors:  H Grabowski
Journal:  Pharmacoeconomics       Date:  1997-05       Impact factor: 4.981

Review 6.  No cure, no pay.

Authors:  Claus Møldrup
Journal:  BMJ       Date:  2005-05-28

Review 7.  Neurobiological applications of small molecule screening.

Authors:  Andras Bauer; Brent Stockwell
Journal:  Chem Rev       Date:  2008-05-01       Impact factor: 60.622

8.  Clinical development success rates for investigational drugs.

Authors:  Michael Hay; David W Thomas; John L Craighead; Celia Economides; Jesse Rosenthal
Journal:  Nat Biotechnol       Date:  2014-01       Impact factor: 54.908

9.  Site of reactivity models predict molecular reactivity of diverse chemicals with glutathione.

Authors:  Tyler B Hughes; Grover P Miller; S Joshua Swamidass
Journal:  Chem Res Toxicol       Date:  2015-03-16       Impact factor: 3.739

Review 10.  Issues in noninferiority trials: the evidence in community-acquired pneumonia.

Authors:  Thomas R Fleming; John H Powers
Journal:  Clin Infect Dis       Date:  2008-12-01       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.